The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Deirdre Cohen on When to Treat Gastric Cancer Patients With Immunotherapies

Deirdre Cohen, MD
Published Online: 9:17 PM, Mon November 9, 2015


Deirdre Cohen, MD, assistant professor of medicine, NYU Langone's Laura and Isaac Perlmutter Cancer Center, talks about the increasingly big role of immunotherapies in the treatment of patients with gastric cancers. Cohen says single agents used in patients with the subtype of gastric cancer that show higher levels of PD-L1 and PD-L2 expression, will most likely get the most benefit out of treatment.


Cohen adds that immunotherpies used in conjunction with other agents are more likely to be useful in the treatment of other types of gastric cancer outside those showcasing PD-L1 and PD-L2 expression. She also notes that according to the TCGA classifications, there are four subtypes of gastric cancers.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.